Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics.
Leuk Lymphoma
; 43(5): 953-9, 2002 May.
Article
em En
| MEDLINE
| ID: mdl-12148905
ABSTRACT
Targeting CD22 on human B-cells with a monoclonal antibody conjugated to a cytotoxic RNAse causes potent and specific killing of the lymphoma cells in vitro. This translates to anti-tumor effects in human lymphoma models in SCID mice. RNA damage caused by RNAses could be an important alternative to standard DNA-damaging chemotherapeutics. A second generation construct with an improved recombinant cytotoxic RNAse is described. Targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant or bacterial toxin-containing immunoconjugates.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Ribonucleases
/
Moléculas de Adesão Celular
/
Imunotoxinas
/
Linfoma de Células B
/
Lectinas
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2002
Tipo de documento:
Article